Life sciences company Thermo Fisher (NYSE:TMO) will be reporting earnings tomorrow before the bell. Here’s what to expect.
Thermo Fisher beat analysts’ revenue expectations by 1% last quarter, reporting revenues of $11.4 billion, up 4.7% year on year. It was a mixed quarter for the company, with an impressive beat of analysts’ organic revenue estimates but a significant miss of analysts’ operating income estimates.
Is Thermo Fisher a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Thermo Fisher’s revenue to decline 1.1% year on year to $10.23 billion, improving from the 3.4% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $5.10 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Thermo Fisher has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Thermo Fisher’s peers in the life sciences tools & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Danaher posted flat year-on-year revenue, beating analysts’ expectations by 2.7%, and Medpace reported revenues up 9.3%, topping estimates by 6%.
Read our full analysis of Danaher’s results here and Medpace’s results here.
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.